2023 ESG Report - Bristol Myers Squibb

image1
image1
image2
image2
image2



“BMS has long been committed to corporate responsibility, and our refined ESG strategy is the result of the commitment by the entire organization to advance our sustainability. Together, we are building a legacy that combines our rich history with a future of innovation, responsibility and growth.”


Christopher S. Boerner, Ph.D.
Board Chair and CEO at Bristol Myers Squibb 

Letter from our Board Chair and CEO

Chris Boerner


ENVIRONMENTAL, SOCIAL AND GOVERNANCE


As of July 2024, BMS' third party verified (limited assurance) 2023 environmental metrics are available. Click here to learn more about our ESG strategy, commitments and progress against our goals.

Read the 2023 Report

 

Our ESG strategy

 


Our ESG strategy is interconnected to our company's core strategy by focusing on three core pillars:
 

ESG can support long-term value creation, and, when needed, we will adapt our business model so we are best positioned to address the shared challenges that society faces on environmental, social and governance issues — and to do so with a science-led, innovation-focused approach that is rooted in health equity. 


 


“We take our obligation to build and maintain trust with our stakeholders very seriously. Our ESG commitments are our compact with society — we hold ourselves accountable to these standards, and to making a meaningful and measurable impact in the communities where we live and work.”


Cari Gallman
Executive Vice President of Corporate Affairs at Bristol Myers Squibb

 

Recent ESG highlights

 

 


12M+
 

people reached through BMS'
health equity grants (2020-2023)

11
 

emerging market brands
(EMBs) filed

>80
 

Low- and middle-income countries
(LMICs) have potential direct import
(DI) access for 12 BMS medicines


58%
 

of clinical trial sites1 were located in
highly diverse area's of the U.S.

26%
 

racially diverse clinical trial participants,
exceeding target goal of 20%

~12.3M
 

patients reached globally2


11
 

approvals in the U.S., E.U.
and Japan

~41%
 

of BMS employees are members of
one or more People and Business Resource Groups (PBRGs)

47.4%
 

of BMS employees at the
executive level are female


Nearly

9000
 

volunteer hours logged by BMS employees worldwide

In 2023,
BMS published
its first

TCFD report
 
Announced a second
15-year Virtual Power Purchasing Agreement (VPPA)
with National Grid Renewables for 145 megawatts (MW) of solar

References

1Defined as 30%+ non-white;

2 Excluding established brands (Baraclude®, Abraxane®, Vidaza®, Reyataz® and Nulojix®)

 

Our stories

 

 





Materiality ESG topics and stakeholder engagement


In early 2023, we partnered with a third-party agency and conducted a global, double ESG materiality assessment to determine which ESG topics are of the highest priority — or “most material” — to our stakeholders. Additional objectives of the materiality assessment were to inform business priorities and our ESG strategy, identify emerging areas of opportunity, enhance risk management, increase transparency, improve resource allocation, and inform reporting disclosures. After completing the assessment, we published our 2023 Global ESG Double Materiality Assessment report, which discloses our key takeaways, our objectives, our approach and methodology, and analysis of our results and observations.